Can immunogenic chemotherapies relieve cancer cell resistance to immune checkpoint inhibitors?
- 1Institut National de la Santé et de la Recherche Médicale (INSERM), France
The unprecedented clinical activity of checkpoint blockade in several types of cancers has formally demonstrated that anti-tumor immune responses are crucial in cancer therapy. Durable responses seen in patients treated with immune checkpoint inhibitors (ICI) show that they can trigger the establishment of long-lasting immunologic memory. This beneficial outcome is however achieved for a limited number of patients. In addition, late relapses are emerging suggesting the development of acquired resistances that compromise the anticancer efficacy of ICI. How can this be prevented through combination therapies? We here review the functions of immune checkpoints, the successes of ICI in treating cancer and their therapeutic limits. We discuss how conventional cancer therapies can be properly selected to set up combinatorial approaches with ICI leading to treatment improvement. We finally summarize clinical data showing the ongoing progress in cancer treatment involving ICI and chemotherapy combination strategies.
Keywords: chemotherapy, checkpoint, Immunomodulation, Cancer, T cells
Received: 21 Feb 2019;
Accepted: 09 May 2019.
Edited by:Nurit Hollander, Tel Aviv University, Israel
Copyright: © 2019 Rivera Vargas and Apetoh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. Lionel Apetoh, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France, firstname.lastname@example.org